Published in Cancer Biol Ther on April 24, 2008
Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res (2010) 2.15
Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One (2010) 1.26
Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol (2012) 1.23
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A (2011) 1.19
Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12
MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1. Protein Cell (2012) 1.10
Inhibitor of κB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. J Biol Chem (2011) 1.10
Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol (2012) 1.08
Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther (2011) 1.07
Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog (2013) 1.07
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J Virol (2014) 1.03
Interferon-λ in HCV Infection and Therapy. Viruses (2010) 0.98
Distinct and overlapping genomic profiles and antiviral effects of Interferon-λ and -α on HCV-infected and noninfected hepatoma cells. J Viral Hepat (2012) 0.97
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect (2014) 0.96
Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res (2010) 0.94
Bacterial pathogens activate a common inflammatory pathway through IFNλ regulation of PDCD4. PLoS Pathog (2013) 0.94
Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3. J Virol (2014) 0.91
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther (2010) 0.88
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J Infect Dis (2011) 0.87
A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol (2011) 0.87
STAT2: A shape-shifting anti-viral super STAT. JAKSTAT (2013) 0.86
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells. PLoS One (2013) 0.85
Ligand-independent interaction of the type I interferon receptor complex is necessary to observe its biological activity. Cytokine (2013) 0.83
Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1). J Biol Chem (2013) 0.83
IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol (2013) 0.82
Efficient co-expression of bicistronic proteins in mesenchymal stem cells by development and optimization of a multifunctional plasmid. Stem Cell Res Ther (2011) 0.80
Relevance of interleukin-10RB to chronic hepatitis B virus infection and biological activities of interferon-λ and interleukin-22. Hepatol Int (2012) 0.79
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. J Clin Transl Hepatol (2013) 0.79
The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. Hepat Mon (2016) 0.79
Efficacy of IFN-λ1 to protect human airway epithelial cells against human rhinovirus 1B infection. PLoS One (2014) 0.78
IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System. PLoS One (2015) 0.78
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. Biomed Res Int (2015) 0.77
IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection. J Immunol (2014) 0.77
Important Role of the IL-32 Inflammatory Network in the Host Response against Viral Infection. Viruses (2015) 0.76
EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV Infection. Mediators Inflamm (2015) 0.75
IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. J Invest Dermatol (2015) 0.75
Lambda Interferons: New Cytokines with Old Functions. Pharmaceuticals (Basel) (2010) 0.75
Interferon Lambda: Modulating Immunity in Infectious Diseases. Front Immunol (2017) 0.75
Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation. Oncol Lett (2015) 0.75
Microbial pathogenesis and type III interferons. Cytokine Growth Factor Rev (2016) 0.75
Interferon-λs: Front-Line Guardians of Immunity and Homeostasis in the Respiratory Tract. Front Immunol (2017) 0.75
Increased expression of IL-28RA mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Rheumatol (2015) 0.75
Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism. J Virol (2017) 0.75
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
Interferons, interferon-like cytokines, and their receptors. Immunol Rev (2004) 6.21
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21
Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet (1995) 4.19
Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 3.25
The SOCS box: a tale of destruction and degradation. Trends Biochem Sci (2002) 2.64
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55
Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 2.27
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 2.05
Function of Stat2 protein in transcriptional activation by alpha interferon. Mol Cell Biol (1996) 1.79
Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res (2006) 1.52
Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol (2005) 1.52
The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem (2006) 1.45
Immunotherapy for renal cell carcinoma. Eur Urol (2003) 1.32
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol (2006) 1.28
Stat3 is required for the development of skin cancer. J Clin Invest (2004) 1.26
Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun (2006) 1.17
The interferon receptors. Semin Oncol (1997) 0.94
Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase. J Biol Chem (2001) 0.91
Stat3 activation is required for cell proliferation and tumorigenesis but not for cell viability in cutaneous squamous cell carcinoma cell lines. Exp Dermatol (2006) 0.91
Cells previously desensitized to type 1 interferons display different mechanisms of activation of stat-dependent gene expression from naïve cells. J Biol Chem (2003) 0.89
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Function of mitochondrial Stat3 in cellular respiration. Science (2009) 5.13
The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol (2004) 2.81
Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol (2007) 2.50
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res (2006) 2.34
Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol (2007) 2.07
General nature of the STAT3-activated anti-inflammatory response. J Immunol (2006) 1.90
Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe (2011) 1.86
Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity. J Exp Med (2008) 1.83
Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81
Interferon-beta reduces proteinuria in experimental glomerulonephritis. J Am Soc Nephrol (2007) 1.63
Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol (2005) 1.57
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci (2010) 1.53
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
Calcium-dependent activation of interleukin-21 gene expression in T cells. J Biol Chem (2005) 1.47
Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses (2004) 1.42
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41
Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem (2004) 1.38
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol (2011) 1.33
IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res (2014) 1.32
Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol (2004) 1.32
Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J Biol Chem (2006) 1.31
Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One (2010) 1.29
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol (2006) 1.28
Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol (2004) 1.28
Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol (2002) 1.27
Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol (2005) 1.25
Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol (2012) 1.23
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem (2006) 1.23
Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun (2007) 1.21
Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology (2012) 1.20
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17
Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol (2012) 1.17
Analysis of white blood cell counts in mice after gamma- or proton-radiation exposure. Radiat Res (2011) 1.16
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A (2009) 1.15
Regulation of the dephosphorylation of Stat6. Participation of Tyr-713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem (2002) 1.13
Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol (2009) 1.13
Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res (2010) 1.10
Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol (2010) 1.10
Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem (2009) 1.09
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res (2011) 1.09
Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev (2010) 1.03
Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci U S A (2012) 1.03
Leishmania donovani-induced expression of suppressor of cytokine signaling 3 in human macrophages: a novel mechanism for intracellular parasite suppression of activation. Infect Immun (2003) 1.01
Monitoring the transition from the T to the R state in E.coli aspartate transcarbamoylase by X-ray crystallography: crystal structures of the E50A mutant enzyme in four distinct allosteric states. J Mol Biol (2004) 1.01
A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell (2007) 1.01
Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. J Biol Chem (2008) 0.99
Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood (2011) 0.98
Interleukin-10 induces uteroglobin-related protein (UGRP) 1 gene expression in lung epithelial cells through homeodomain transcription factor T/EBP/NKX2.1. J Biol Chem (2004) 0.98
A novel role for IL-22R1 as a driver of inflammation. Blood (2010) 0.98
Cecal ligation puncture procedure. J Vis Exp (2011) 0.95
Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Natl Cancer Inst (2002) 0.95
Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol (2006) 0.95
Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. PLoS Pathog (2011) 0.94
Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif (2004) 0.93
STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) (2010) 0.92
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J Pharmacol Exp Ther (2011) 0.92
Induction of uteroglobin-related protein 2 (Ugrp2) gene expression by the Th2 cytokines IL-4 and IL-13. J Immunol (2005) 0.92
Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J Biol Chem (2011) 0.90
IL-4 engagement of the type I IL-4 receptor complex enhances mouse eosinophil migration to eotaxin-1 in vitro. PLoS One (2012) 0.90
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90
Control of type I interferon-induced cell death by Orai1-mediated calcium entry in T cells. J Biol Chem (2011) 0.89
Cells previously desensitized to type 1 interferons display different mechanisms of activation of stat-dependent gene expression from naïve cells. J Biol Chem (2003) 0.89
Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res (2010) 0.89
Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res (2013) 0.87
Leukocyte activity is altered in a ground based murine model of microgravity and proton radiation exposure. PLoS One (2013) 0.87
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies. Proc Natl Acad Sci U S A (2012) 0.87
TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells. J Immunol (2010) 0.86
Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor. J Biol Chem (2011) 0.86
Interferon β induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice. Brain (2013) 0.86
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Proc Natl Acad Sci U S A (2013) 0.86
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem (2013) 0.84
Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. Virol J (2012) 0.84
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther (2014) 0.84
The role of signal transducer and activator of transcription-2 in the interferon response. J Interferon Cytokine Res (2012) 0.84
IRF7-dependent IFN-β production in response to RANKL promotes medullary thymic epithelial cell development. J Immunol (2013) 0.83
PEGylated interferon-beta modulates the acute inflammatory response and recovery when combined with forced exercise following cervical spinal contusion injury. Exp Neurol (2010) 0.83
Purifying the hedgehog protein and its variants. Methods Mol Biol (2007) 0.83
Identification of STAT2 serine 287 as a novel regulatory phosphorylation site in type I interferon-induced cellular responses. J Biol Chem (2012) 0.82
Interferon-β modulates type 1 immunity during influenza virus infection. Antiviral Res (2010) 0.80
Sonic hedgehog signalling in neurons of adult ventrolateral nucleus tractus solitarius. Eur J Neurosci (2005) 0.80
Type I interferons activate apoptosis in a Jurkat cell variant by caspase-dependent and independent mechanisms. Cell Signal (2005) 0.80